Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORLESTRIN FE 1/50 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone acetate provides negative feedback on gonadotropin release, suppressing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg plus ferrous fumarate 75 mg) orally once daily for 28 days, with 21 active tablets and 7 placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 5-12 hours (mean 8 hours). Ethinyl estradiol: 11-16 hours. Clinical context: Steady state reached in 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone acetate: extensively metabolized via reduction (to active 5α-dihydro derivatives), hydroxylation, and conjugation; primarily by CYP3A4. Ethinyl estradiol: metabolized by CYP3A4 via hydroxylation and conjugation; undergoes enterohepatic circulation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone: 20% renal, 80% fecal. Ethinyl estradiol: 40% renal, 60% fecal.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 97% bound (albumin, SHBG). Ethinyl estradiol: 97% bound (albumin, SHBG, CBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 2-4 L/kg; reflects tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64%, Ethinyl estradiol ~38% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No specific GFR-based dose modifications are recommended. Use with caution in patients with renal impairment or history of renal disease.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to reduced clearance and risk of adverse effects.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated in pediatric patients before menarche. In adolescents, dosing is the same as adults (one tablet daily). Safety and efficacy in post-menarcheal adolescents are similar to adults.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated in geriatric patients. No specific dose adjustment; however, consider age-related risks (e.g., thromboembolism, cardiovascular disease). Use lowest effective dose if necessary.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from combined hormonal contraceptive use, especially in women over 35 years who smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (DVT, PE, stroke, MI), hepatic neoplasia, gallbladder disease, carbohydrate/lipid effects, hypertension, hereditary angioedema, chloasma, retinal thrombosis (discontinue if sudden vision loss/proptosis/diplopia), depression.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis/venous thromboembolism (current or history), arterial thromboembolic disease (e.g., stroke, MI), cerebrovascular disease, coronary artery disease, valvular heart disease with complications, thrombogenic arrhythmias, diabetes with vascular involvement, severe hypertension, liver tumors or active liver disease, undiagnosed abnormal uterine bleeding, known or suspected pregnancy, breast cancer, hypersensitivity to components, jaundice with prior OC use, heavy smoking (>15 cigarettes/day) in women over 35.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may increase estrogen levels via CYP3A4 inhibition; avoid large quantities. No specific food restrictions, but high-fat meals may delay absorption. Iron absorption is reduced by calcium-rich foods, tea, and coffee; take iron tablets separately from these.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Category X. Not indicated for use during pregnancy. First trimester: No increased risk of birth defects from inadvertent use; however, use is contraindicated. Second and third trimesters: Androgenic steroid exposure may cause feminization of male fetus, genital abnormalities, and potential long-term effects; no safe use established.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk in small amounts. M/P ratio not established. May reduce milk production and quality. Use is not recommended during breastfeeding. Consider alternative contraception.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustment applicable. If pregnancy occurs, discontinue immediately.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Withdrawal bleeding typically occurs during the iron-only tablet phase; absence of bleeding requires pregnancy testing. Iron supplementation in active tablets may cause GI upset. CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce contraceptive efficacy. Venous thromboembolism risk is higher with estrogen-containing pills; avoid in migraine with aura or hypertension.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time; the last 7 tablets contain iron, not hormones.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 2 hours, or have severe diarrhea.,This does not protect against STIs; use condoms for prevention.,Report sudden severe headache, chest pain, leg swelling, or vision changes immediately.,Iron tablets may cause constipation or dark stools; this is normal.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORLESTRIN FE 1/50 vs AFIRMELLE, answered by our medical review team.
NORLESTRIN FE 1/50 is a Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone acetate provides negative feedback on gonadotropin release, suppressing ovulation. Also causes cervical mucus thickening and endometrial thinning.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORLESTRIN FE 1/50 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORLESTRIN FE 1/50 is: One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg plus ferrous fumarate 75 mg) orally once daily for 28 days, with 21 active tablets and 7 placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORLESTRIN FE 1/50 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORLESTRIN FE 1/50 is classified as Category C. Category X. Not indicated for use during pregnancy. First trimester: No increased risk of birth defects from inadvertent use; however, use is contraindicated. Second and third trim. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.